Gian Maria Busetto1, Matteo Ferro2, Francesco Del Giudice1, Gabriele Antonini1, Benjamin I Chung3, Isabella Sperduti4, Diana Giannarelli4, Giuseppe Lucarelli5, Marco Borghesi6, Gennaro Musi7, Ottavio de Cobelli7, Ettore De Berardinis1. 1. Department of Gynecological-Obstetrics Sciences and Urological Sciences, Sapienza Rome University Policlinico Umberto I, Rome, Italy. 2. Department of Urology, European Institute of Oncology (IEO), Milan, Italy. Electronic address: matteo.ferro@ieo.it. 3. Department of Urology, Stanford University Medical Center, Stanford, CA. 4. Biostatistical Unit, Regina Elena National Cancer Institute, Rome, Italy. 5. Department of Emergency and Organ Transplantation, Urology, Andrology, and Kidney Transplantation Unit, University of Bari, Bari, Italy. 6. Department of Urology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. 7. Department of Urology, European Institute of Oncology (IEO), Milan, Italy.
Abstract
INTRODUCTION: The purpose of this study was to evaluate the impact of circulating tumor cells (CTCs) as a prognostic marker in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) and assess the efficacy and reliability of 2 different CTC isolation methods. MATERIALS AND METHODS: Globally, 155 patients with a pathologically confirmed diagnosis of high-risk NMIBC were included (pT1G3 with or without carcinoma in situ) and underwent transurethral resection of bladder tumor (TURB) after a blood withdrawal for CTC evaluation. A total of 101 patients (Group A) had their samples analyzed with the CellSearch automated system, and 54 (Group B) had their samples analyzed with the CELLection Dynabeads manual system. RESULTS: Patients were followed for 28 months, and during this interval, there were a total of 65 (41.9%) recurrences, 27 (17.4%) disease progressions, and 9 (5.8%) lymph node and/or bone metastasis. In our CTC analysis, there were 20 (19.8%) positive patients in Group A and 24 in Group B (44.4%). In our analysis, we found a strong correlation between CTC presence and time to first recurrence; in Group A, we observed an incidence of recurrence in 75% of CTC-positive patients and in Group B of 83% of CTC-positive patients. The time to progression was also strongly correlated with CTCs: 65% and 29%, respectively, of those patients who progressed in those with CTCs in Group A and B. CONCLUSION: The study demonstrates the potential role of CTCs as a prognostic marker for risk stratification in patients with NMIBC, to predict both recurrence and progression.
INTRODUCTION: The purpose of this study was to evaluate the impact of circulating tumor cells (CTCs) as a prognostic marker in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) and assess the efficacy and reliability of 2 different CTC isolation methods. MATERIALS AND METHODS: Globally, 155 patients with a pathologically confirmed diagnosis of high-risk NMIBC were included (pT1G3 with or without carcinoma in situ) and underwent transurethral resection of bladder tumor (TURB) after a blood withdrawal for CTC evaluation. A total of 101 patients (Group A) had their samples analyzed with the CellSearch automated system, and 54 (Group B) had their samples analyzed with the CELLection Dynabeads manual system. RESULTS:Patients were followed for 28 months, and during this interval, there were a total of 65 (41.9%) recurrences, 27 (17.4%) disease progressions, and 9 (5.8%) lymph node and/or bone metastasis. In our CTC analysis, there were 20 (19.8%) positive patients in Group A and 24 in Group B (44.4%). In our analysis, we found a strong correlation between CTC presence and time to first recurrence; in Group A, we observed an incidence of recurrence in 75% of CTC-positive patients and in Group B of 83% of CTC-positive patients. The time to progression was also strongly correlated with CTCs: 65% and 29%, respectively, of those patients who progressed in those with CTCs in Group A and B. CONCLUSION: The study demonstrates the potential role of CTCs as a prognostic marker for risk stratification in patients with NMIBC, to predict both recurrence and progression.
Authors: Nico C Grossmann; Pawel Rajwa; Fahad Quhal; Frederik König; Hadi Mostafaei; Ekaterina Laukhtina; Keiichiro Mori; Satoshi Katayama; Reza Sari Motlagh; Christian D Fankhauser; Agostino Mattei; Marco Moschini; Piotr Chlosta; Bas W G van Rhijn; Jeremy Y C Teoh; Eva Compérat; Marek Babjuk; Mohammad Abufaraj; Pierre I Karakiewicz; Shahrokh F Shariat; Benjamin Pradere Journal: Eur Urol Open Sci Date: 2022-04-01